Skip to main content
. 2019 Jul 9;8(7):997. doi: 10.3390/jcm8070997

Figure 5.

Figure 5

Clinical trial design proposal for a risk-driven personalized approach. NDMM: newly-diagnosed MM. RRMM: relapsed-refractory MM. ASCT: autologous stem cell transplantation. Allo-SCT: allogeneic stem cell transplantation. MRD: minimal residual disease. * FISH, NGS (genomic panels including known actionable mutation and TP53 mutation), and GEP. ** FISH, NGS (genomic panels including known actionable mutation and TP53 mutation and drug resistance-related genomic alterations), and GEP. CAR-T: Chimeric Antigen Receptor T cell; BiTE: Bispecific T cell engager antibody; tandem ASCT: double autologous stem cell transplantation. Tandem ASCT is already being investigated in experimental studies.